0000000000751107

AUTHOR

D. J. Stewart

showing 2 related works from this author

Cross-hemispheric transport of central African biomass burning pollutants: implications for downwind ozone production

2010

Pollutant plumes with enhanced concentrations of trace gases and aerosols were observed over the southern coast of West Africa during August 2006 as part of the AMMA wet season field campaign. Plumes were observed both in the mid and upper troposphere. In this study we examined the origin of these pollutant plumes, and their potential to photochemically produce ozone (O<sub>3</sub>) downwind over the Atlantic Ocean. Their possible contribution to the Atlantic O<sub>3</sub> maximum is also discussed. Runs using the BOLAM mesoscale model including biomass burning carbon monoxide (CO) tracers were used to confirm an origin from central African biomass burning fires. The…

Wet seasonbiomass burningAtmospheric ScienceOzone010504 meteorology & atmospheric sciences[SDE.MCG]Environmental Sciences/Global Changes010501 environmental sciencesAtmospheric sciences01 natural sciences7. Clean energyWest africalcsh:ChemistryTroposphere010309 opticschemistry.chemical_compoundWest Africa0103 physical sciencesBiomass burningField campaign0105 earth and related environmental sciencesPollutant[PHYS.PHYS.PHYS-AO-PH]Physics [physics]/Physics [physics]/Atmospheric and Oceanic Physics [physics.ao-ph]Atmosphärische Spurenstoffelcsh:QC1-999Trace gaslcsh:QD1-999chemistry13. Climate actionClimatologyEnvironmental sciencelcsh:Physics
researchProduct

Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter …

2001

PURPOSE: To study the additional benefit from adenoviral p53 gene therapy in patients undergoing first-line chemotherapy for advanced non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Twenty-five patients with nonresectable NSCLC were enrolled in an open-label, multicenter phase II study of three cycles of regimen A, carboplatin (area under the curve, 6; day 1) plus paclitaxel (175 mg/m2, day 1), or regimen B, cisplatin (100 mg/m2, day 1) plus vinorelbine (25 mg/m2, days 1, 8, 15, and 22) in combination with intratumoral injection of 7.5 × 1012 particles of SCH 58500 (rAd/p53, day 1). Responses of individual tumor lesions were assessed after each cycle, and gene transfer was examin…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyPathologyLung NeoplasmsPaclitaxelmedicine.medical_treatmentGenetic VectorsPhases of clinical researchVinorelbineAdenoviridaeCarboplatinchemistry.chemical_compoundInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancerAgedCisplatinChemotherapybusiness.industryGenetic transferGenetic TherapyMiddle Agedmedicine.diseaseGenes p53Survival AnalysisCarboplatinRegimenTreatment OutcomeOncologychemistryDisease ProgressionFemaleCisplatinbusinessmedicine.drug
researchProduct